abstract |
The present invention relates to an anti-CTLA4 conjugate or a pharmaceutically acceptable salt thereof, wherein said conjugate comprises a plurality of anti-CTLA4 moieties -D covalently conjugated via at least one moiety -L1-L2- to a polymeric moiety Z, wherein -L1- is covalently and reversibly conjugated to -D and -L2- is covalently conjugated to Z and wherein -L1- is a linker moiety and -L2- is a chemical bond or a spacer moiety; and related aspects. |